PubRank

B Velan

Author PubWeight™ 53.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs. Proc Natl Acad Sci U S A 1981 6.67
2 Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001 2.67
3 Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 2000 1.93
4 Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. J Biol Chem 1993 1.72
5 Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr 2000 1.47
6 Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. EMBO J 1992 1.43
7 Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J 1996 1.41
8 Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene 1992 1.28
9 Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun 2002 1.26
10 Evidence for P-N bond scission in phosphoroamidate nerve agent adducts of human acetylcholinesterase. Biochemistry 2000 1.21
11 Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem 1994 1.14
12 Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun 2003 1.11
13 Exploring the active center of human acetylcholinesterase with stereomers of an organophosphorus inhibitor with two chiral centers. Biochemistry 1999 1.05
14 Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. J Virol 1989 1.04
15 Engineering resistance to 'aging' of phosphylated human acetylcholinesterase. Role of hydrogen bond network in the active center. FEBS Lett 1993 1.04
16 Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase. J Biol Chem 2000 1.03
17 Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase. J Biol Chem 1995 1.03
18 Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J 1998 1.00
19 The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors. J Biol Chem 1996 1.00
20 Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite. Biochemistry 1995 1.00
21 Interrelations between assembly and secretion of recombinant human acetylcholinesterase. J Biol Chem 1993 1.00
22 Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines. Infect Immun 2003 1.00
23 Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation. Biochem J 1995 0.99
24 The "back door" hypothesis for product clearance in acetylcholinesterase challenged by site-directed mutagenesis. J Biol Chem 1994 0.99
25 Electrostatic attraction by surface charge does not contribute to the catalytic efficiency of acetylcholinesterase. EMBO J 1994 0.95
26 Evaluation of anchorage-dependent cell propagation systems for production of human acetylcholinesterase by recombinant 293 cells. Cytotechnology 1993 0.95
27 Resolving pathways of interaction of covalent inhibitors with the active site of acetylcholinesterases: MALDI-TOF/MS analysis of various nerve agent phosphyl adducts. Chem Res Toxicol 2001 0.94
28 Functional characteristics of the oxyanion hole in human acetylcholinesterase. J Biol Chem 1998 0.93
29 Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 2005 0.93
30 Effect of human acetylcholinesterase subunit assembly on its circulatory residence. Biochem J 2001 0.90
31 The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem J 1998 0.89
32 Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. Biochem J 2001 0.89
33 Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine 2005 0.87
34 Does "butyrylization" of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase? Biochemistry 2001 0.87
35 Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase. Mol Pharmacol 1994 0.86
36 Specific residues within an amino-terminal domain of 35 residues of interferon alpha are responsible for recognition of the human interferon alpha cell receptor and for triggering biological effects. J Biol Chem 1987 0.86
37 Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives. Mol Pharmacol 1996 0.86
38 Bovine acetylcholinesterase: cloning, expression and characterization. Biochem J 1998 0.85
39 Overexpressed monomeric human acetylcholinesterase induces subtle ultrastructural modifications in developing neuromuscular junctions of Xenopus laevis embryos. J Neurochem 1994 0.84
40 Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus. Vaccine 1991 0.82
41 Bovine interferon alpha genes. Structure and expression. J Biol Chem 1985 0.81
42 Direct determination of the chemical composition of acetylcholinesterase phosphonylation products utilizing electrospray-ionization mass spectrometry. FEBS Lett 1997 0.80
43 Theoretical and experimental investigations of electrostatic effects on acetylcholinesterase catalysis and inhibition. Chem Biol Interact 1999 0.80
44 Aging of somanyl-acetylcholinesterase adducts: facts and models. Biochem J 1997 0.79
45 Divergent envelope E2 alphavirus sequences spanning amino acids 297 to 352 induce in mice virus-specific protective immunity and antibodies with complement-mediated cytolytic activity. J Virol 1992 0.76
46 Rapid identification and quantitation of small numbers of microorganisms by a chemiluminescent immunoreaction. Appl Environ Microbiol 1977 0.76
47 Alphavirus hybrid virion vaccines. Adv Exp Med Biol 1996 0.75
48 Chemiluminescence immunoassay: a new sensitive method for determination of antigens. Immunochemistry 1978 0.75
49 Cloning of a bovine interferon-alpha gene subfamily and comparisons between genetically engineered and leukocyte bovine interferons. Dev Biol Stand 1985 0.75
50 Cloning, expression and biological activity of a new variant of human interferon alpha identified in virus induced lymphoblastoid cells. Dev Biol Stand 1985 0.75
51 Protection of cattle from infection with vaccinia virus by bovine interferon alpha C. Vet Rec 1989 0.75
52 Production of monoclonal antibodies toward bovine interferons-alpha suitable for immunopurification. J Interferon Res 1989 0.75
53 Mutations not altering the symmetrical sequences in the trp operator yield a constitutive phenotype. Mol Gen Genet 1984 0.75
54 Isolation of bovine IFN-alpha genes and their expression in bacteria. Methods Enzymol 1986 0.75
55 Serologically defined linear epitopes in the E2 envelope glycoprotein of Semliki Forest virus. Arch Virol 1990 0.75
56 Genetic engineering of human interferons from lymphoblastoid cells: III. Purification, physicochemical and biological properties of bacterial IFN-alpha J1. Adv Biotechnol Processes 1985 0.75
57 Induction and characterization of bovine leukocyte interferon. Methods Enzymol 1986 0.75
58 Genetic engineering of human interferons from lymphoblastoid cells: I. Cloning of interferon species expressed in Sendai-induced Namalva cells. Adv Biotechnol Processes 1985 0.75
59 Genetic engineering of human interferons from lymphoblastoid cells: II. Construction of trp expression plasmids and their use for efficient expression of IFN-alpha J1. Adv Biotechnol Processes 1985 0.75